E156 Micro-Paper · Africa Clinical Trials

Southern African Research Arc

The Southern African arc is anchored by South Africa's world-class research infr...

Africa Trials
3,515
US Trials
159,433
Gap Ratio
45x
Gini
0.637
The Gini coefficient of 0.637 indicates severe concentration, with most trials confined to a handful of nations.
Southern African Research Arc by Country Egypt: N/A Algeria: N/A Morocco: N/A Tunisia: N/A Senegal: N/A Ghana: N/A Nigeria: N/A Cameroon: N/A DRC: N/A Ethiopia: N/A Kenya: N/A Uganda: N/A Tanzania: 460 Rwanda: N/A South Africa: 3654 Sou 3654 Tan 460 106 3654
Southern African Research Arc Lorenz Curve 0% 0% 25% 25% 50% 50% 75% 75% 100% 100% Gini = 0.637
Regional Comparison Africa US Europe 0 50000 100000 150000 200000
Contribution Breakdown 3654 South Afri 460 Tanzania 344 Malawi 307 Zambia 201 Zimbabwe 376 Others
No data
Research Profile Volume Growth Phase3 Complete Diversity Equity
Enrollment Distribution Africa Reference 5000 10000 15000 20000
Enrollment Density Africa Reference 10000 20000 30000
Why It Matters

The Southern African arc is anchored by South Africa's world-class research infrastructure — SAMRC, Wits, UCT — but this dominance means that SADC neighbours receive spillover rather than sovereign capacity.

In the spatial mapping of African clinical research, does the pattern of southern african research arc reveal structural inequity in African research investment? This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.gov through April 2026. Investigators computed the power-law exponent as the primary estimand using registry metadata for each nation. The distribution yielded a Gini coefficient of 0.637 (95% CI 204.25-2166.26), indicating severe concentration of trials among a small number of nations. Shannon entropy of the trial distribution was 1.73 bits, confirming substantial concentration beyond random variation. These findings reveal a geographic research monopoly where most African nations remain functionally invisible in the clinical evidence landscape. Interpretation is constrained by missing sub-national data and the exclusion of observational studies from the analysis.
Question

In the spatial mapping of African clinical research, does the pattern of southern african research arc reveal structural inequity in African research investment?

Dataset

This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.

Method

gov through April 2026.

Primary Result

Investigators computed the power-law exponent as the primary estimand using registry metadata for each nation.

Robustness

The distribution yielded a Gini coefficient of 0.

Interpretation

637 (95% CI 204.

Boundary

25-2166.

Extra

26), indicating severe concentration of trials among a small number of nations.

Extra

Shannon entropy of the trial distribution was 1.

Extra

73 bits, confirming substantial concentration beyond random variation.

Extra

These findings reveal a geographic research monopoly where most African nations remain functionally invisible in the clinical evidence landscape.

Extra

Interpretation is constrained by missing sub-national data and the exclusion of observational studies from the analysis.